linjc16/ctgov huggingface dataset:
Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Lung cancer is the commonest malignant disease with a 5-year survival of 14%. In Hong Kong, it accounts for about 30% of all cancer death. The poor prognosis of lung cancer is due largely to the late clinical presentation of the disease. In order to improve the prognosis of lung cancer, an obvious approach is to develop sensitive methods for detecting lung cancer at much earlier stages when treatment is more likely to be curative. However, the best way for identifying early lung cancer is still need to be determined. We hypothesis that by examining specimens that contain shed bronchial epithelial cells i.e. sputum, lung cancer can be sampled in its earliest possible phase. And by using autofluorescence bronchoscopy, a system specifically designed to detect early lung cancer/pre-invasive lesions, to identify the source of abnormal cells, we may able to detect eraly lung cancer and followed by curative treatment to improve the prognosis of this disease.

Official Title
-----------------
Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer

Conditions
-----------------
Lung Neoplasms

Intervention / Treatment
-----------------
* Procedure: Bronchoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Current or ex-smokers who have smoked at least 20-pack-years (e.g. 1 pack per day for 20 years or more) Informed consent Exclusion Criteria: Known malignant disease Unstable major medical disease Bleeding disorder Unwilling to have a bronchoscopy Women currently pregnant or nursing Known reaction to xylocaine, a local anaesthesia agent used for bronchoscopy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Bronchoscopy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of early stage lung cancer/precancerous lesion detected |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung cancer
Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game

Study Overview
=================
Brief Summary
-----------------
Participants will play a computer game that is controlled by their gaze patterns and designed to direct attention their attention to specific on-screen targets. Visual attention to targets will be rewarded. Both visual behavior and brain response will be recorded during game play. It is hypothesized that that, over the course of the game, relative to baseline, participants will show (a) increased looking to targets, (b) decreased response time to targets, and (c) enhanced, more efficient neural response to visual cues. It is hypothesized that clinical variability will associate with visual attention and brain response.

Conditions
-----------------
Neurodevelopmental Disorders

Intervention / Treatment
-----------------
* Behavioral: Game


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to participate in an eye-tracking experiment Able to participate in an EEG experiment Exclusion Criteria: Sensory or physical impairment that would preclude completion of protocol Participants taking prescription medications that may affect cognitive processes Participants reporting significant head trauma or history of seizures
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Game<br>Participants will play a video game directing their gaze to on-screen targets. | Behavioral: Game<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EEG brain response to targets |  | Measures will be recorded for the duration of their visit, an expected average of 3 hours. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual attention to targets as measured by eye-tracking |  | Measures will be recorded for the duration of their visit, an expected average of 3 hours. | 
| Social Responsiveness Scale, Second Edition |  | Measures will be collected during visit, an expected average of 3 hours. | 
| Autism Diagnostic Observation Schedule |  | Measures will be collected during visit, an expected average of 3 hours. | 
| Differential Abilities Scale |  | Measures will be collected during visit, an expected average of 3 hours. | 
| Vineland Adaptive Behavior Scales, Second Edition |  | Measures will be collected during visit, an expected average of 3 hours. | 
| Social Anxiety Scale for Children, Revised |  | Measures will be collected during visit, an expected average of 3 hours. |
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is determine the minimal effective dose and the impact on: treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode the final maintenance doses the use of other medications the amount of changes to other antipsychotic medication the number of hospitalization days

Official Title
-----------------
A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years.

Conditions
-----------------
Psychosis

Intervention / Treatment
-----------------
* Drug: Quetiapine Fumarate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients experiencing their first psychotic episode Male or Female Aged 15-25 Exclusion Criteria: Previous treatment with antipsychotic medication (longer than 1 week) History of a clinically significant physical illness Organic disorder presenting with psychotic symptoms

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Quetiapine Fumarate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medication dose, Remission and response rate, exBPRSvs4, SANS, CGI - I, CGI - S, CDSS, GAF and QoL scale |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SWN, UKU, illicit substance use, laboratory measures, altered drop-out rates |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
First Episode Psychosis
Changes in Brain Activity (Functional MRI Study) Before and After Behavioral Therapy of Height Phobia

Study Overview
=================
Brief Summary
-----------------
We are interested in investigating the functional brain abnormalities of height phobia. Subjects will be have a functional MRI scan before and after a course of treatment with behavioral therapy.

Detailed Description
-----------------
The purpose of this study is to investigate the effects of in vivo exposure therapy on the functional brain activity of subjects with height phobia using a fear provocation paradigm. We expect differential activation of the fear circuitry in height phobics compared to non-phobic controls, and that successful behavioral therapy will normalize the heightened fear response in height phobia.

Official Title
-----------------
The Effects of in Vivo Exposure Therapy on the Neural Correlates of Height Phobia: a Functional Magnetic Resonance Imaging Study Using a Fear Provocation Paradigm.

Conditions
-----------------
Height Phobia, Fear of Heights

Intervention / Treatment
-----------------
* Behavioral: Behavior therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Specific phobia of Heights Exclusion Criteria: History of medical problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Behavior therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CGI |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acrophobia questionnaire |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Height phobia, fear of heights, specific phobia
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics and pharmacodynamics of insulin X14 30/70 PreMix compared to human insulin 30/70 PreMix in healthy volunteers.

Official Title
-----------------
A Randomised, Double-blind 2 Way Crossover Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Insulin X14 30/70 PreMix Compared to Human Insulin 30/70 PreMix in Healthy Volunteers

Conditions
-----------------
Diabetes, Healthy

Intervention / Treatment
-----------------
* Drug: biphasic insulin aspart 30
* Drug: biphasic human insulin 30


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-smokers BMI (body mass index) maximum 27 kg/m^2 HbA1c (glycosylated haemoglobin A1c): 3.4-6.1% FBG (fasting blood glucose) maximum 6.0 mmol/L

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment period 1<br> | Drug: biphasic insulin aspart 30<br>* One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order<br>Drug: biphasic human insulin 30<br>* One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order<br>|
| Active Comparator: Treatment period 2<br> | Drug: biphasic insulin aspart 30<br>* One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order<br>Drug: biphasic human insulin 30<br>* One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the Curve |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum insulin concentration (Cmax) |  |  | 
| Time to maximum insulin concentration (tmax) |  |  | 
| Minimum glucose concentration (Cmin(glu)) |  |  | 
| Time to minimum glucose concentration (tmin(glu)) |  |  | 
| Adverse events |  |  |
Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.

Official Title
-----------------
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Conditions
-----------------
Schizophrenia, Iloperidone, Efficacy

Intervention / Treatment
-----------------
* Drug: iloperidone
* Drug: Risperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women ages 18-65 years old. DSM-IV diagnosis of schizophrenia. PANSS≥70. Of the 7 PANSS positive symptom subscale, at least two score ≥ 4 points. Written informed consent. Exclusion Criteria: Pregnant or nursing (lactating) women, or women who plan on conceiving during the course of the study. Clinically significant disease of the heart,kidneys,liver,hematonosis or endocrine system.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Risperidone<br> | Drug: Risperidone<br>* Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.<br>|
| Experimental: iloperidone<br> | Drug: iloperidone<br>* Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive and Negative Symptom Scale(PANSS)-Total Score |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effective percentage(PANSS score reduce rate≥50%) |  | 6 weeks | 
| Change in scores from baseline to end point assessment on the PANSS Positive subscale (PANSS-P) |  | 6 weeks | 
| Change in scores from baseline to end point assessment on the PANSS Negative subscale (PANSS-N) |  | 6 weeks | 
| Change in scores from baseline to end point assessment on the PANSS General Psychopathology subscale(PANSS-GP) |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, iloperidone, Risperidone, Efficacy, Safety
Prosthetic Motility and Complications in Pegged Versus Unpegged Hydroxyapatite Orbital Implants

Study Overview
=================
Brief Summary
-----------------
Pegging the hydroxyapatite for increasing prosthetic motility sometimes leads to some complications for the patient. These complications ranging from discharge, granuloma formation, exposure, implant infection to socket discomfort and etc. We are going to compare prosthetic motility, objectively and subjectively (patients satisfaction) before and after pegging the hydroxy- apatite, and evaluate the complications after pegging.

Conditions
-----------------
Anophthalmos, Orbital Implants

Intervention / Treatment
-----------------
* Procedure: orbital implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: orbital hydroxyapatite implants Exclusion Criteria: history of systemic disease history of radio therapy secondary hydroxapatite implant complications lead to re-surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Pegged unpegged hydroxyapatite orbital implantation | Procedure: orbital implant<br>* Implantation of pegged versus unpegged hydroxyapatite orbital implants<br>|
| Active Comparator: 2<br>Unpegged hydroxyapatite orbital implantation | Procedure: orbital implant<br>* Implantation of pegged versus unpegged hydroxyapatite orbital implants<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changing movement in up gaze: 0.58 mm |  |  | 
| Changing movement in down gaze: 0.83 mm |  |  | 
| Changing movement in medial gaze: 0.75 mm |  |  | 
| Changing movement in lateral gaze: 1.2 mm |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hydroxyapatite, peg, prosthetic motility, orbital implant
The Impact of Lifestyle on Sperm Telomere Length and Telomerase Activity in Men Undergoing IVF Treatments

Study Overview
=================
Brief Summary
-----------------
This aim of this study is to determine the impact of lifestyle on telomere length and telomerase enzyme activity on sperm cells of men undergoing IVF treatments.

Detailed Description
-----------------
Following approval of the study by the Hospital Ethical Committee (Helsinki), semen samples and blood will be collected from infertile individuals referred to our IVF unit at Hillel Yaffe Medical Center. Informed written consent will be obtained from each participant. Standard semen analysis will be carried out according to World Health Organization protocol. An aliquot of semen sample will be used for assessment of sperm motility, concentration, and morphology by using computer-aided sperm analysis (CASA) and the remaining sample will be used for assessment of sperm telomere lengths and telomerase activity. Genomic DNA will be extracted from the remaining washed sperm and peripheral blood. Sperm telomere length will be determined by real-time polymerase chain reaction (qRT-PCR) and telomerase activity will be determined by TRAP assay (Telomeric Repeat Amplification Protocol).

Official Title
-----------------
Investigating the Impact of Lifestyle on Telomere Length and Telomerase Activity on Sperm Cells Originating From Infertile Men Undergoing IVF Treatment

Conditions
-----------------
Male Infertility

Intervention / Treatment
-----------------
* Other: DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infertile couple Exclusion Criteria: Chronic disease Azoospermia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infertile men<br>Men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia) | Other: DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).<br>* DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Telomere length | After laboratory determination of telomere length, results will be compared to lifestyle of subject to see whether smoking or other lifestyle behaviors have an effect | Two years |
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore and examine endpoints that allow evaluation of the clinically significant improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms by this drug in patients with diarrhea-predominant irritable bowel syndrome (IBS).

Official Title
-----------------
Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Drug: Ramosetron
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients meeting the Rome III Diagnostic Criteria Loose (mushy) or watery stools within the last 3 months Exclusion Criteria: Patients having hyperthyroidism or hypothyroidism

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ramosetron group<br>oral | Drug: Ramosetron<br>* oral<br>* Other names: YM060;|
| Placebo Comparator: Placebo group<br>oral | Drug: Placebo<br>* oral<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IBS severity index (Japanese version) |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient reported global assessment of relief of IBS symptoms |  | 12 weeks | 
| Patient reported assessment of relief of abdominal discomfort and/or pain |  | 12 weeks | 
| Patient reported assessment of improvement of abdominal bowel habits |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diarrhea, IBS, Colonic diseases, YM060